DE29709820U1 - Special food additive - Google Patents
Special food additiveInfo
- Publication number
- DE29709820U1 DE29709820U1 DE29709820U DE29709820U DE29709820U1 DE 29709820 U1 DE29709820 U1 DE 29709820U1 DE 29709820 U DE29709820 U DE 29709820U DE 29709820 U DE29709820 U DE 29709820U DE 29709820 U1 DE29709820 U1 DE 29709820U1
- Authority
- DE
- Germany
- Prior art keywords
- carnitine
- arginine
- food additive
- special food
- pyridoxine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000013373 food additive Nutrition 0.000 title claims description 17
- 239000002778 food additive Substances 0.000 title claims description 17
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 8
- 229930064664 L-arginine Natural products 0.000 claims description 8
- 235000014852 L-arginine Nutrition 0.000 claims description 8
- 235000008160 pyridoxine Nutrition 0.000 claims description 8
- 239000011677 pyridoxine Substances 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 159000000003 magnesium salts Chemical class 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 4
- 229960003035 magnesium gluconate Drugs 0.000 claims description 4
- 239000001755 magnesium gluconate Substances 0.000 claims description 4
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 4
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 claims description 3
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims description 3
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 claims description 2
- 244000309464 bull Species 0.000 claims 2
- 230000002265 prevention Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000036314 physical performance Effects 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Preparation And Processing Of Foods (AREA)
Description
&tgr;&egr;&tgr; /6&tgr;&egr;&tgr; /6
Lebensmittel-SpezialzusatzSpecial food additive
Bereich der Technik
5 Area of technology
5
Die Erfindung betrifft einen Lebensmittel-Spezialzusatz sowohl für Leistungs- und Spitzensportler als auch fur Normalverbraucher.The invention relates to a special food additive for both competitive and top athletes as well as for normal consumers.
Bisheriger Zustand der TechnikCurrent state of technology
Zur Unterstützung von Leistungstraining, langfristigen Leistungen, zur Regeneration des Organismus, event, zur Vorbeugung einiger Zivilisationskrankheiten werden verschiedene Lebensmittelzusätze genutzt. Den Grundbestandteil bilden meistens Aminosäuren, vor allem Arginin und Carnitin, die mit speziellen Zusätzen, die zur besseren Nutzung der Aminosäuren bestimmt sind, kombiniert werden. Weiter werden sie mit Vitaminen oder Mineralien in verschiedenen Formen ergänzt, die eine katalytische und unterstützende Wirkung haben.Various food additives are used to support performance training, long-term performance, regenerate the body, and prevent certain lifestyle diseases. The basic components are usually amino acids, especially arginine and carnitine, which are combined with special additives designed to improve the use of amino acids. They are then supplemented with vitamins or minerals in various forms that have a catalytic and supportive effect.
Man bemüht sich, einen Lebensmittelzusatzes in einer solchen Zusammensetzung zu entwickeln, die die metabolischen Vorgänge und die Immunitätsreaktion des Organismus beim breiten Spektrum der Benutzer positiv beeinflussen kann.Efforts are being made to develop a food additive with a composition that can positively influence the metabolic processes and immune response of the organism in a wide range of users.
Den genannten Anforderungen entspricht ein Lebensmittelspezialzusatz, derThe above requirements are met by a special food additive which
L-Carnitin und L-Arginin beinhaltet. Das erfindungsgmäße Prinzip liegt darin, daß der Lebensmittelzusatz zusätzlich zumindest L-Glyzin und Pyridoxin enthält, und zwar in den jeweiligen Mengen:Contains L-carnitine and L-arginine. The principle of the invention is that the food additive additionally contains at least L-glycine and pyridoxine, in the respective amounts:
L-Carnitin 50 bis 2000 mg, L-Arginin 50 bis 2000 mg, L-Glycin 50 bis 2000 mg, Pyridoxin 1 bis 20 mg; event, wird mit organischem Magnesiumsalz in der Menge 50 - 5000 mg ergänzt. L-Carnitin kann als L-Carnitin base oder als L-Carnitin Tartrat oder als L-Carnitin Hydrochlorid, L-Arginin als L-Arginin base oder L-Arginin Hydrochlorid oder L-Arginin Aspertat enthalten sein. Organisches Magnesiumsalz ist als Magnesiumglukonat enthalten und Pyridoxin als Pyridoxin Hydrochlorid, Zur weiteren Wirkung des Lebensmittelspezialzusatzes gehört die positive Beeinflussung der organischen metabolischen Prozesse, Unterstützung der Immunitätsreaktion des Organismus, Unterstützung der Hirn- und Herztätigkeit, Vorbeugung der Muskeldystrophie.L-carnitine 50 to 2000 mg, L-arginine 50 to 2000 mg, L-glycine 50 to 2000 mg, pyridoxine 1 to 20 mg; event, is supplemented with organic magnesium salt in the amount of 50 - 5000 mg. L-carnitine can be contained as L-carnitine base or as L-carnitine tartrate or as L-carnitine hydrochloride, L-arginine as L-arginine base or L-arginine hydrochloride or L-arginine aspartate. Organic magnesium salt is contained as magnesium gluconate and pyridoxine as pyridoxine hydrochloride. The other effects of the special food additive include the positive influence on organic metabolic processes, support of the organism's immune response, support of brain and heart activity, prevention of muscular dystrophy.
Beispiel einer AusführungExample of an execution
Zum besseren Fettabbau und zur Unterstützung der Herztätigkeit eignet sich am besten L-Carnitin base 6000 mg, L-Arginin base 2000 mg, L-Glycin 1000 mg, Magnesiumglukonat 2000 mg und Pyridoxin Hydrochlorid 40 mg in 300 ml Wasserlösung.For better fat loss and to support heart function, the best options are L-carnitine base 6000 mg, L-arginine base 2000 mg, L-glycine 1000 mg, magnesium gluconate 2000 mg and pyridoxine hydrochloride 40 mg in 300 ml water solution.
Aminosäuren werden mit synergisierendem Vitamin B und mit Magnesiumionen ergänzt.Amino acids are supplemented with synergistic vitamin B and magnesium ions.
Empfehlenswerte Tagesdosis der genannten Lösung ist 15 bis 60 ml, gewöhnlich in zwei Gaben verteilt. Es ist zu empfehlen, die Lösung mit Vitamin C, Propolis, Selen oder Juwin zu kombinieren, was den Immunisierungs- und Antistressefekt verstärkt.The recommended daily dose of the solution is 15 to 60 ml, usually divided into two doses. It is recommended to combine the solution with vitamin C, propolis, selenium or Juwin, which enhances the immunization and anti-stress effect.
Je nach Bestimmung des Lebensmittelzusatzes und der physischen oder
psychischen Belastung können die einzelnen Bestandteile des Lebensmittelzusatzes
in folgenden Mengen eingenommen werden:
L-Camitin 50 bis 2000 mg,
L-Arginin 50 bis 2000 mg,
L-Glycin 50 bis 2000 mg,Depending on the purpose of the food additive and the physical or psychological stress, the individual components of the food additive can be taken in the following quantities:
L-Carnitine 50 to 2000 mg,
L-Arginine 50 to 2000 mg,
L-Glycine 50 to 2000 mg,
Magnesiumsalz 50 bis 5000 mg,Magnesium salt 50 to 5000 mg,
Pyridoxin 1 bis 20 mgPyridoxine 1 to 20 mg
als Tagesdosis oder in 1 bis 10 ml wässriger Lösung.as a daily dose or in 1 to 10 ml aqueous solution.
L-Carnitin kann als L-Carnitin base oder L-Carnitin Tartrat oder L-CarnitinL-carnitine can be taken as L-carnitine base or L-carnitine tartrate or L-carnitine
Hydrochlorid anwesend sein, L-Arginin ist als L-Arginin base enthalten oder als L-Arginin Hydrochlorid oder L-Arginin Aspertat, Magnesiumsalz ist als Magnesium -glukonat und Pyridoxin ist als Pyridoxin Hydrochlorid enthalten. Der Lebensmittel-Spezialzusatz ist zur Verwendung für die breite Öffentlichkeit, für Leistungsportler als unterstützendes Mittel bei Problemgewicht und Fettleibigkeit, zur Vorbeugung der Herzkrankheiten, zur Erhöhung der psychischen und körperlichen Leistung und der Immunität des Organismus bestimmt. Weiterhin zur Senkung des Cholesterolspiegels und zur Normalisierung des Blutzuckerspiegels, vor allem bei Diabetes-Patienten. Bei älterer und mittlerer Generation ist er zur Unterstützung der Hirn- und Herztätigkeit und als Vorbeugung oder Rekonvaleszenz bei Hirnschlag, zur Vorbeugung und Rekonvaleszenz von Muskeldystrophie, Nachtmuskelspannungen, Beinkrämpfen und Händekribbeln, event. Gliedmaßennervenentzündungen geeignet. Er ist auchHydrochloride may be present, L-arginine is contained as L-arginine base or as L-arginine hydrochloride or L-arginine aspartate, magnesium salt is contained as magnesium gluconate and pyridoxine is contained as pyridoxine hydrochloride. The special food additive is intended for use by the general public, for competitive athletes as a supportive agent for problem weight and obesity, for the prevention of heart disease, for increasing mental and physical performance and the body's immunity. It is also intended for lowering cholesterol levels and normalizing blood sugar levels, especially in diabetes patients. For older and middle-aged generations it is suitable for supporting brain and heart function and as a prevention or convalescence after a stroke, for the prevention and convalescence of muscular dystrophy, night muscle tension, leg cramps and tingling in the hands, and possibly limb nerve inflammation. It is also
zur Entgiftung und zur Stärkung des Organismus nach Intoxikation, einschließlich Alkohol, bestimmt. Bei Sportlern unterstützt er physische Leistungsfähigkeit und Muskelwachstum, senkt die Herzfrequenz nach einer anstrengenden körperlichen Leistung, schützt die Muskeln und hat krampfvorbeugende Wirkung.intended for detoxification and strengthening the body after intoxication, including alcohol. In athletes, it supports physical performance and muscle growth, lowers the heart rate after strenuous physical activity, protects muscles and has an anti-spasmodic effect.
Der Lebensmittei-Spezialzusatz kann für die breite Öffentlichkeit industriell hergestellt werden.The special food additive can be manufactured industrially for the general public.
Claims (4)
L-Arginin 50 bis 2000 mg,
L-Glycin 50 bis 2000 mg,
Pyridoxin 1 bis 20 mg
als Tagesdosis oder in 1 bis 10 ml wässriger Lösung. 1. Special food additive containing L-carnitine and L-arginine, characterized in that the special food additive additionally contains at least L-glycine and pyridoxine, in the following amounts: L-carnitine 50 to 2000 mg,
L-Arginine 50 to 2000 mg,
L-Glycine 50 to 2000 mg,
Pyridoxine 1 to 20 mg
as a daily dose or in 1 to 10 ml aqueous solution.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ542896 | 1996-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE29709820U1 true DE29709820U1 (en) | 1997-07-31 |
Family
ID=5468448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE29709820U Expired - Lifetime DE29709820U1 (en) | 1996-06-10 | 1997-06-05 | Special food additive |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE29709820U1 (en) |
| PL (1) | PL320472A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999007388A1 (en) * | 1997-08-08 | 1999-02-18 | Mccarty Mark F | Method for promoting weight and fat loss with a composition comprising hydroxycitrate, carnitine and a pyruvate promotor |
| WO2000045651A1 (en) * | 1999-02-02 | 2000-08-10 | Novartis Nutrition Ag | Oral arginine and insulin secretion |
| FR2794647A1 (en) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | PHARMACEUTICAL COMPOSITIONS COMPRISING NO OR AT LEAST A COMPOUND CAPABLE OF RELEASING OR INDUCING THE FORMATION OF NO IN CELLS |
| WO2002021934A1 (en) * | 2000-09-18 | 2002-03-21 | Lonza Ag | Use of carnitine for enhancing training-induced bradycardia |
| WO2003006008A1 (en) * | 2001-07-10 | 2003-01-23 | Penam Investments Pty Ltd | A method for treatment and/or prophylaxis |
| EP1541041A1 (en) * | 2003-12-10 | 2005-06-15 | Synergia Holding | Pharmaceutical and/or dietary compositions against stress |
-
1997
- 1997-06-05 DE DE29709820U patent/DE29709820U1/en not_active Expired - Lifetime
- 1997-06-10 PL PL97320472A patent/PL320472A1/en unknown
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999007388A1 (en) * | 1997-08-08 | 1999-02-18 | Mccarty Mark F | Method for promoting weight and fat loss with a composition comprising hydroxycitrate, carnitine and a pyruvate promotor |
| WO2000045651A1 (en) * | 1999-02-02 | 2000-08-10 | Novartis Nutrition Ag | Oral arginine and insulin secretion |
| US6143786A (en) * | 1999-02-02 | 2000-11-07 | Novartis Nutrition Ag | Oral arginine and insulin secretion |
| WO2000076451A3 (en) * | 1999-06-11 | 2002-06-20 | Centre Nat Rech Scient | Pharmaceutical composition comprising no or at least a no donor compound inducing no formation in cells |
| WO2000076451A2 (en) * | 1999-06-11 | 2000-12-21 | Centre National De La Recherche Scientifique - Cnrs | Pharmaceutical composition comprising no or at least a no donor compound inducing no formation in cells |
| FR2794647A1 (en) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | PHARMACEUTICAL COMPOSITIONS COMPRISING NO OR AT LEAST A COMPOUND CAPABLE OF RELEASING OR INDUCING THE FORMATION OF NO IN CELLS |
| JP2003506320A (en) * | 1999-06-11 | 2003-02-18 | センター ナショナル デ ラ レシェルルシェ サイエンティフィック−シーエヌアールエス | Pharmaceutical compositions comprising NO or at least one NO donating compound or other compound capable of releasing NO or inducing NO formation in cells |
| US6872751B2 (en) | 1999-06-11 | 2005-03-29 | Centre National De La Recherche Scientifique - Cnrs | Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof |
| WO2002021934A1 (en) * | 2000-09-18 | 2002-03-21 | Lonza Ag | Use of carnitine for enhancing training-induced bradycardia |
| AU2002213931B2 (en) * | 2000-09-18 | 2006-04-13 | Lonza Ag | Use of carnitine for enhancing training-induced bradycardia |
| WO2003006008A1 (en) * | 2001-07-10 | 2003-01-23 | Penam Investments Pty Ltd | A method for treatment and/or prophylaxis |
| EP1541041A1 (en) * | 2003-12-10 | 2005-06-15 | Synergia Holding | Pharmaceutical and/or dietary compositions against stress |
| FR2863497A1 (en) * | 2003-12-10 | 2005-06-17 | Synergia Holding | NEW PHARMACEUTICAL AND / OR DIETETIC COMPOSITIONS AGAINST STRESS |
Also Published As
| Publication number | Publication date |
|---|---|
| PL320472A1 (en) | 1997-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69828881T2 (en) | COMPOSITION TO TREAT DISORDERS OF HUMAN HEALTH IN HEALTHY INDIVIDUALS | |
| DE2634900C2 (en) | 3-Trihydroxygermylpropionic acid, its salts and process for their preparation | |
| DE3882135T2 (en) | USE OF MELATONIN OR ITS DERIVATIVES FOR THE PRODUCTION OF MEDICINAL PRODUCTS THAT ARE EFFECTIVE AGAINST AGE DISEASES. | |
| WO2012120036A1 (en) | Orthomolecular agent for countering the consequences of alcohol consumption | |
| DE3875867T2 (en) | CALCIUM ADDITIVES. | |
| EP2222292A2 (en) | Novel use of omega-3-fatty acid(s) | |
| DE29709820U1 (en) | Special food additive | |
| DE3880587T2 (en) | USE OF CERTAIN CALCIUM-CITRATE MALATES FOR THE PRODUCTION OF A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF OSTEOPOROSIS. | |
| AT513274B1 (en) | Dietary supplements | |
| DE60124769T2 (en) | FOOD SUPPLEMENT WITH SLIMMING EFFECT | |
| EP0496479B1 (en) | NADH and NADPH as energy-substitutes | |
| DE60124516T2 (en) | COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID | |
| DE60213237T2 (en) | USE OF L-ACETYLCARNITINE IN COMBINATION WITH BIOTIN FOR THE TREATMENT OF PATIENTS WITH INSULIN RESISTANT DIABETES MELLITUS TYPE II | |
| DE2642768C2 (en) | ||
| DE2759108A1 (en) | USE OF ALPHA -MERCAPTO-BETA-ARYL-ACRYLIC ACIDS IN INCREASING THE ZINC CONTENT IN SERUM AND TISSUE | |
| DE69936056T2 (en) | FOOD SUPPLEMENT CONTAINING LIPONIC ACID AND CREATINE AND METHODS FOR THEIR APPLICATION | |
| DE102009052808A1 (en) | Ointment, useful e.g. for treating salt deficiency, acute and chronic trauma, comprises ointment base and homeopathically diluted mineral salt including e.g. calcium phosphate, iron phosphate, potassium chloride and potassium phosphate | |
| DE10215007A1 (en) | Use of creatine pyruvate to increase endurance during high-intensity physical interval workouts | |
| DE69914395T2 (en) | Dietary supplements | |
| DE69912383T2 (en) | Medicinal products, in particular for dietetic use, containing pyruvic acid derivatives and an extract of the immature bitter orange | |
| DE60216090T2 (en) | USE OF L-ACETYLCARNITINE FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF ANHEDONIA | |
| EP0018550A2 (en) | Compositions for muscular disease treatment | |
| Şahin et al. | Impairment of motor coordination in mice after ingestion of aluminum chloride | |
| DE202017006840U1 (en) | Dietary supplement comprising a galactose-containing multivitamin-mineral complex | |
| EP0291751B1 (en) | Pharmaceutical mixture preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 19970911 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 20000623 |
|
| R081 | Change of applicant/patentee |
Owner name: NUTREND D.S., A.S., CZ Free format text: FORMER OWNER: NUTREND, S.R.O., OLOMOUC, CZ Effective date: 20020221 |
|
| R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20030610 |
|
| R152 | Utility model maintained after payment of third maintenance fee after eight years |
Effective date: 20050630 |
|
| R071 | Expiry of right |